The Patent Finder

Oral Testosterone Tridecanoate Therapy

Lipocine Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 15/828,320, filed Nov 30, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,881,670Oral Testosterone Tridecanoate Therapy
In force (reinstated)
 · High confidence
Lipocine Inc.In force (reinstated)
High confidence
US 11,992,496Oral Testosterone Therapy
In force
 · High confidence
Lipocine, Inc.In force
High confidence
US 12,161,651Oral Testosterone Therapy
In force
 · Low confidence
Lipocine Inc.In force
Low confidence
US 12,303,517Oral Testosterone Therapy
In force
 · Low confidence
Lipocine, Inc.In force
Low confidence
US 11,672,807Oral Testosterone Non-Undecanoate Therapy
In force
 · High confidence
Lipocine Inc.In force
High confidence
Application 15/828,320Oral Testosterone Tridecanoate Therapy
Abandoned
Abandoned Jan 2, 2020
Lipocine Inc.AbandonedAbandoned Jan 2, 2020
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Lipocine Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited